Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Line Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006

NCT02428608
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
DWP-450 (Botulinum purified neurotoxin, Type A)
Biological
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

NCT03150862
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Pamiparib, TMZ, Radiation
Drug · Radiation
Lead sponsor
BeiGene USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
ambrisentan, tadalafil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)

NCT00392054
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pulmonary Vein Isolation performed by Catheter Ablation, Conventional Antiarrhythmic Drug Therapy
Procedure · Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
19 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Results available

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

NCT03742258
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, Rituximab, Spleen Tyrosine Kinase Inhibitor TAK-659, Vincristine Sulfate
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 30, 2026, 12:09 PM EDT
Completed No phase listed Observational

Developing and Maintaining a Central Venous Catheter Registry

NCT01165411
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
Not listed
Enrollment
4,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Results available

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

NCT04074343
View directory record Official record
Conditions
Gastric Adenocarcinoma, GastroEsophageal Cancer
Interventions
TAS-102, Irinotecan
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Orange, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

NCT00288418
View directory record Official record
Conditions
Bacterial Infections
Interventions
Central Venous Catheter
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Phase 3 Interventional

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574
View directory record Official record
Conditions
Lung Cancer, Non-squamous, Non-small Cell
Interventions
zongertinib, pembrolizumab, cisplatin, carboplatin, pemetrexed
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Huntsville, Alabama • Bullhead City, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

NCT03439462
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional

Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia

NCT00011505
View directory record Official record
Conditions
Diamond Blackfan Anemia
Interventions
G-CSF, Leukapheresis
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968942
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1 Interventional

Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

NCT02010606
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
Interventions
Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Not applicable Interventional

Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study

NCT00250809
View directory record Official record
Conditions
Other Female Genital, Cancer
Interventions
Placement of a central venous catheter
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Phase 1 Interventional

GDNF Gene Therapy for Multiple System Atrophy

NCT04680065
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Biological · Procedure
Lead sponsor
Brain Neurotherapy Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2Phase 3 Interventional

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT00401323
View directory record Official record
Conditions
Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
Interventions
docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 20, 2011 · Synced Oct 30, 2026, 12:09 PM EDT
Not listed Not applicable Interventional

Ethanol Lock for Prevention of Central Line-Associated Blood Stream Infections

NCT01344590
View directory record Official record
Conditions
Central Lines in ICU Patients
Interventions
Normal Saline, Ethanol 70% pharmaceutical grade
Other
Lead sponsor
University of Virginia
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2011 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated No phase listed Observational

Frequency of Accessing Central Lines for Blood Samples

NCT00366314
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
30 Days to 18 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 1 Interventional

Micafungin Lock Therapy

NCT00809887
View directory record Official record
Conditions
Catheter-Related Fungal Infections
Interventions
Micafungin lock therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine and Pembrolizumab in Pancreatic Cancer

NCT03264404
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Pembrolizumab, Azacitidine
Drug
Lead sponsor
Susan E. Bates
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Glue Versus Suture for Securing Radial Arterial Lines

NCT06589284
View directory record Official record
Conditions
Arterial Catheters, Catheter Related Complication
Interventions
Silk 0-0 suture covered by chlorhexidine gluconate dressing, 2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing
Procedure
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834
View directory record Official record
Conditions
Glabellar Lines
Interventions
AI-09 Ready Use Injectable Botulinum Toxin, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
20 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Aventura, Florida • West Palm Beach, Florida • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1 Interventional

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

NCT01082926
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Ependymoblastoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Grade III Meningioma, Meningeal Hemangiopericytoma, Mixed Glioma, Pineal Gland Astrocytoma, Brain Tumor
Interventions
therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 12:09 PM EDT